Publications by authors named "Fathallah H"

The quark-gluon plasma analysis relies on the heavy quark potential, which is influenced by the anisotropic plasma parameter temperature (t), and baryonic chemical potential (μ). Employing the generalized fractional derivative Nikiforov-Uvarov (GFD-NU) method, we solved the topologically-fractional Schrödinger equation. Two scenarios were explored: the classical model (α = β = 1) and the fractional model (α, β < 1).

View Article and Find Full Text PDF
Article Synopsis
  • The study focused on glioblastoma, IDH-wildtype, examining survival rates and factors influencing long-term survival in patients diagnosed between 2000 and 2021.
  • The median overall survival was found to be 11.2 months, with only 17.6% of patients surviving 2 years and a mere 2.2% surviving 5 years.
  • Two key factors for improved survival included receiving standard combined chemoradiotherapy and having a methylated O6-methylguanine-DNA methyltransferase promoter, along with age and specific imaging characteristics at diagnosis.
View Article and Find Full Text PDF

Background And Objectives: We assessed the impact of ventricular opening on postoperative complications and survival of carmustine wafer implantation during surgery of newly diagnosed supratentorial glioblastomas, isocitrate dehydrogenase (IDH)-wildtype in adults.

Methods: We performed an observational, retrospective, single-center cohort study at a tertiary surgical neuro-oncological center between January 2006 and December 2021.

Results: One hundred ninety-four patients who benefited from a first-line surgical resection with carmustine wafer implantation were included.

View Article and Find Full Text PDF
Article Synopsis
  • - This study evaluated the safety and effectiveness of Carmustine wafer implantation in elderly patients (over 80) and those with low performance status (Karnofsky score < 50) undergoing surgery for newly diagnosed glioblastoma, showing no increase in complications or negative impacts on treatment completion.
  • - Results indicated that using 12 or more Carmustine wafers improved progression-free and overall survival rates significantly, with progression-free survival extended from 10 to 31 months and overall survival from 16.5 to 39 months.
  • - The findings suggest that Carmustine wafer implantation is both safe and beneficial for these high-risk patients, with a recommendation to adjust the number of wafers used based on the size of
View Article and Find Full Text PDF

Cranioplasty is important for improving cosmesis and functional recovery after decompressive craniectomy. We assessed the incidence and predictors of post-cranioplasty epidural hematomas requiring surgical evacuation. A single-institution, retrospective study enrolled 194 consecutive patients who underwent a cranioplasty using custom-made hydroxyapatite between February 2008 and April 2022.

View Article and Find Full Text PDF

Background: In the last two decades, high-altitude training (HAT) and elevation training masks (ETMs) have been widely used among athletes to enhance physical performance. However, few studies have examined the effect of wearing ETMs on physiological and hematological parameters in different sports.

Aims: The present study aimed to investigate the impact of ETM use in athletes on several hematological and physiological indicators among cyclists, runners, and swimmers.

View Article and Find Full Text PDF

Brillouin fiber sensors have demonstrated strong capability in discriminative and high-sensitivity multiparameter measurements. In this study, we proposed and numerically investigated novel ring core fiber-based stimulated Brillouin scattering for the simultaneous measurement of temperature and strain. The novel fiber, referred to as ring hyperbolic tangent (R-HTAN) fiber, is characterized by a shape parameter (α) that controls the optical refractive index and longitudinal acoustic velocity profiles.

View Article and Find Full Text PDF

Background: Several studies suggest that patients with KRAS-mutant NSCLC fail to benefit from standard systemic therapies and do not respond to EGFR inhibitors. Most recently, KRAS 12c data suggest specific treatment for improving ORR and OS. There is a clear need for therapies specifically developed for these patients.

View Article and Find Full Text PDF

Stathmin 1 (STMN1) is a cytosolic phosphoprotein that was discovered as a result of its high level of expression in leukemic cells. It plays an important role in the regulation of mitosis by promoting depolymerization of the microtubules that make up the mitotic spindle and, aging has been shown to impair STMN1 levels and change microtubule stability. We have previously demonstrated that a high level of STMN1 expression during early megakaryopoiesis is necessary for proliferation of megakaryocyte progenitors and that down-regulation of STMN1 expression during late megakaryopoiesis is important for megakaryocyte maturation and platelet production.

View Article and Find Full Text PDF

Background: The combination of everolimus and the imidazoquinoline derivative, BEZ235 (dactolisib), a dual PI3K/mTOR inhibitor, demonstrated synergy in a preclinical model.

Objective: To establish clinical feasibility, a phase Ib dose-escalation trial investigating safety and pharmacokinetics of this combination in patients with advanced tumors was performed.

Patients And Methods: BEZ235 was orally administered daily in escalating doses of 200, 400, and 800 mg along with everolimus at 2.

View Article and Find Full Text PDF

Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in adult patients with hemoglobin disorders. The understanding of the developmental regulation of γ-globin gene expression was followed by the identification of a number of chemical compounds that can reactivate HbF synthesis in vitro and in vivo in patients with hemoglobin disorders. These HbF inducers can be grouped in several classes based on their mechanisms of action.

View Article and Find Full Text PDF

Inducers of fetal hemoglobin (HbF) have shown considerable promise in the treatment of sickle cell disease (SCD). However, the same agents have shown less clinical activity in beta-thalassemia (beta-Thal). To understand the basis of these differences in clinical effectiveness, we compared the effects of butyrate and hemin on the expression of the different globin genes in progenitors-derived erythroid cells from patients with beta-Thal intermedia and SCD.

View Article and Find Full Text PDF

K562 erythroleukemia cells have been widely used as a model for the study of globin gene regulation. A number of agents have been shown to activate or suppress globin gene expression in these cells. However, the molecular effects of these agents on the epigenetic configuration of the alpha- and gamma-globin genes that encode HbF are not known.

View Article and Find Full Text PDF

Butyrate is a prototype of histone deacetylase inhibitors that is believed to reactivate silent genes by inducing epigenetic modifications. Although butyrate was shown to induce fetal hemoglobin (HbF) production in patients with hemoglobin disorders, the mechanism of this induction has not been fully elucidated. Our studies of the epigenetic configuration of the beta-globin cluster suggest that DNA methylation and histone H3 acetylation are important for the regulation of developmental stage-specific expression of the beta-like globin genes, whereas acetylation of both histones H3 and H4 seem to be important for the regulation of tissue-specific expression.

View Article and Find Full Text PDF

Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in patients with hemoglobin disorders. In sickle cell disease (SCD), an increase in HbF inhibits the polymerization of sickle hemoglobin and the resulting pathophysiology. Hydroxyurea, an inducer of HbF, has already been approved for the treatment of patients with moderate and/or severe SCD.

View Article and Find Full Text PDF

Reactivation of fetal hemoglobin (HbF) expression is an important therapeutic option in patients with hemoglobin disorders. In sickle cell disease (SCD), an increase in HbF would interfere with the polymerization of sickle hemoglobin while in beta-thalassemia, an increase in gamma-globin chain synthesis would decrease non-alpha:alpha chain imbalance. Hydroxyurea, an inducer of HbF, is the only currently approved agent for the treatment of patients with moderate and/or severe SCD.

View Article and Find Full Text PDF

The first studies of the pharmacological induction of fetal hemoglobin were conducted in patients with sickle cell disease and thalassemia. Although hydroxyurea was approved by the FDA for the treatment of sickle cell disease in 1996, no similar pharmacological agent(s) has been approved for the treatment of patients with thalassemic disorders. The small-scale studies of the induction of fetal hemoglobin in thalassemia have been generally disappointing.

View Article and Find Full Text PDF

The outlook for patients with sickle cell disease has improved steadily during the last two decades. In spite of these improvements, curative therapies are currently available only to a small minority of patients. The main theme of this chapter is to describe new therapeutic options that are at different stages of development that might result in further improvements in the outlook for patients with these disorders.

View Article and Find Full Text PDF

The signaling cascade linking insulin receptor stimulation to the activation of Na/H exchanger (NHE) was investigated in human erythrocytes, a simple cell model expressing the NHE1 isoform and protein kinase C (PKC) alpha and zeta isoforms only. Our results demonstrate the presence of phosphatidylinositol (PtdIns) 3-kinase in these cells and its activation by insulin. With a similar time-course, insulin also promoted both the translocation and activation of PKC zeta, but had no effect on PKC alpha.

View Article and Find Full Text PDF

KCl cotransport activated by swelling of sickle red blood cells (SS RBC)is inhibited by deoxygenation. Yet recent studies found a Cl--dependent increase in sickle reticulocyte density with cyclic deoxygenation. This study sought to demonstrate cotransporter stimulation by deoxygenation of SS RBC in isotonic media with normal pH.

View Article and Find Full Text PDF

We have previously shown that a pretreatment with phorbol 12-myristate 13-acetate (PMA), an activator of protein kinase C (PKC), reduced deoxygenation-induced K+ loss and Ca2+ uptake and prevented cell dehydration in sickle anemia red blood cells (SS cells) (H. Fathallah, E. Coezy, R.

View Article and Find Full Text PDF

Deoxygenation (DO) of sickle cell anemia red blood cells (SS cells) induces membrane permeabilization to Ca2+, Na+, and K+ and cell dehydration mostly through the activation of the Ca(2+)-dependent K+ channels. We show that DO of both SS cells and normal red blood cells was accompanied by a nonspecific dephosphorylation of membrane proteins. After treatment with a protein kinase C activator (phorbol myristate acetate) or a phosphoprotein phosphatase inhibitor (okadaic acid), the level of membrane protein phosphorylation in deoxygenated cells was maintained higher or equal, respectively, to that of the oxygenated controls.

View Article and Find Full Text PDF